Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Project Patient Voice is going to provide patient-reported symptoms from cancer trials for marketed treatments.
These are the latest cancer treatments approved by the FDA.
FDA advises consumers, patients and health care professionals after new FDA studies show risk to public health.
The FDA offers researchers new guidance to help keep trials on track.
Efficacy of the combination was investigated in a multicenter, multiple cohort, open-label trial conducted in patients with HCC.
Approval was based on a study showing combination treatment reduced disease progression or death by 40%.
The efficacy of Nerlynx with capecitabine was investigated in a randomized, multicenter, open-label clinical trial in 621 people.
The agency reviewed a decade of animal and epidemiological studies in search of such evidence.
Potential risk of cancer outweighs the benefits
The National Cancer Institute stands to lose more than $500 million, and cancer prevention programs are at risk.
Epithelioid sarcoma is a rare sub-type of soft tissue sarcoma that often occurs in young adults.
New research adds to our understanding of sunscreens.
A clinical trial shows a possible increased risk of cancer and the FDA is continuing to evaluate the results.
Clinical trials showed a high response rate, with almost 85% of participants experiencing tumor shrinkage with this targeted drug.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
The drug was previously approved for castration-resistant prostate cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.